✦ LIBER ✦

Mon-P68 - Clinical experience with gabapentin in patients with bipolar disorder: Results of an open label study

✍ Scribed by P.L. Cabras; J. Hardoy; C. Hardoy

Book ID: 119574034
Publisher: Elsevier Science
Year: 1998
Tongue: French
Weight: 242 KB
Volume: 13
Category: Article
ISSN: 0924-9338
DOI: 10.1016/s0924-9338(99)80404-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P.2.079 Open-label study of risperidone

P.2.079 Open-label study of risperidone in children with bipolar disorder

✍ J. Biederman 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 142 KB

An open label clinical trial of reboxeti

An open label clinical trial of reboxetine in patients with major depressive disorder

✍ B. Demir; A. Soykan; H. Devrimci-Ozguven; A. Gögüs; T. Haller 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 127 KB

Omega-3 fatty acids decreased irritabili

Omega-3 fatty acids decreased irritability of patients with bipolar disorder in an add-on, open label study

✍ Kemal Sagduyu; Mehmet E Dokucu; Bruce A Eddy; Gerald Craigen; Claudia F Baldassa 📂 Article 📅 2005 🏛 BioMed Central 🌐 English ⚖ 505 KB

P.2.e.023 Switching from olanzapine to z

P.2.e.023 Switching from olanzapine to ziprasidone in patients with bipolar I disorder: an 8-week, multicenter, open-label study

✍ B. Yoon; M. Kim; H. Lee; Y. Kwon; W. Bahk 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 60 KB

P.1.040 Combination of mood stabilizer w

P.1.040 Combination of mood stabilizer with quetiapine for treatment of acute bipolar disorder: An open label study

✍ W.M. Bahk; K.U. Lee; B.H. Yoon; J.H. Chae; T.Y. Jun; K.S. Kim 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 140 KB

Olanzapine monotherapy for acute depress

Olanzapine monotherapy for acute depression in patients with bipolar I or II disorder: results of an 8-week open label trial

✍ William V. Bobo; Richard A. Epstein; Richard C. Shelton 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 1 views

## Abstract We evaluated the efficacy, tolerability, and safety of olanzapine monotherapy in 20 adult patients with bipolar I or II disorder, depressed phase. Patients received open‐label olanzapine monotherapy (mean modal dose, 15 mg/day) for 8 weeks. Assessments of psychopathology (Montgomery–Asb